MARYLAND SHORT-TERM TAX-FREE BOND FUND MARYLAND SHORT-TERM TAX-FREE BOND FUND (PRMDX US) stock market data APIs
5.1006
0(0%)
as of July 14, 2025
Try our APIs with
free plan!
MARYLAND SHORT-TERM TAX-FREE BOND FUND MARYLAND SHORT-TERM TAX-FREE BOND FUND Financial Data Overview
Price chart is built with
Anychart
Prev. Close
5.1006
Open
5.1006
High
5.1006
Low
5.1006
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MARYLAND SHORT-TERM TAX-FREE BOND FUND MARYLAND SHORT-TERM TAX-FREE BOND FUND data using free add-ons & libraries
End-of-day & Earnings data
Get MARYLAND SHORT-TERM TAX-FREE BOND FUND MARYLAND SHORT-TERM TAX-FREE BOND FUND Earnings data
$
19.99
/mo.
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get MARYLAND SHORT-TERM TAX-FREE BOND FUND MARYLAND SHORT-TERM TAX-FREE BOND FUND End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MARYLAND SHORT-TERM TAX-FREE BOND FUND MARYLAND SHORT-TERM TAX-FREE BOND FUND News
New
MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology
Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb)showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with chemothera...
Downgrade: Here's How Analysts See MacroGenics, Inc. (NASDAQ:MGNX) Performing In The Near Term
The analysts covering MacroGenics, Inc. (NASDAQ:MGNX) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year. Both revenue an...
MacroGenics Announces MGD019 Publication in Cell Reports Medicine
PD-1 × CTLA-4 Bispecific DART® molecule is preliminarily well-tolerated in dose escalation clinical study ROCKVILLE, MD, Dec. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopha...
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeut...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
